NCT07562087 Lotilaner Lyme Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07562087 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07562087 is a hot trial to watch
Lyme Disease is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07562087 is notable because it evaluates Lotilaner in a Phase 2 design sponsored by Tarsus Pharmaceuticals, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07562087 |
| Official title | A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure |
| Phase / status | Phase 2 / Active, not recruiting |
| Intervention | Lotilaner |
| Sponsor | Tarsus Pharmaceuticals, Inc. |
| Geography | United States |
| Enrollment | [object Object] |
| Primary endpoint | The Incidence of Treatment Emergent Adverse Events From Baseline |
| Endpoint time frame | From day 1 through the end of study follow-up, an average of 15 months. |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- The Incidence of Treatment Emergent Adverse Events From Baseline (From day 1 through the end of study follow-up, an average of 15 months.) — Safety and tolerability will be evaluated by incidence rate of treatment emergent adverse events from baseline.
- Clinically Significant Changes From Baseline Chemistry Laboratory Tests (From day 1 through the end of study follow up, an average of 15 months.) — Number of participants with clinically significant changes in clinical laboratory tests
- Clinically Significant Changes From Baseline Hematology Laboratory Tests (From day 1 through the end of study follow up, an average of 15 months.) — Number of participants with clinically significant changes in clinical laboratory tests.
- Clinically Significant Changes From Baseline Vital Signs (From day 1 through the end of study follow up, an average of 15 months.) — Number of participants with clinically significant changes in vital signs.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Lotilaner is indexed as Small molecule drug, with target GluCls, mechanism GluCls inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Tarsus Pharmaceuticals, Inc. did not return an exact normalized organization match in this snapshot. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07562087 provides a focused lens on Lyme Disease development. Its value will be determined by whether Lotilaner can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
